APC and neoplasm: We evaluated the ability of the APC-targeted construct CCL19_Neo13 and the previously published, non-targeted pDNA design, Neo13 (33), to induce neoepitope-specific T cells and tumor control in a prophylactic setting at different pDNA doses.